2 years ago

Camena Bioscience Secures £7.9 Million for DNA Synthesis Platform

  • Camena Bioscience, a health tech startup providing synthetic genes to the pharmaceutical industry, has raised £7.9 million in a Series A funding round led by Mercia

  • The company's enzymatic technology is more accurate and cost effective than traditional DNA synthesis methods

  • The funding will be used to scale operations and continue development of its gSynth synthesis platform.

      • ProblemTechnology

      "Making complex genes accurately is difficult and expensive, limiting the potential of synthetic biology."

      Solution

      "Camena Bioscience has developed a more accurate and cost-effective enzymatic technology for DNA synthesis, enabling researchers to 'write' DNA with the same ease as they can 'read' it."

      Covered on